Wheeler Bio, an Oklahoma City, OK-based contract development and manufacturing organization (CDMO), raised $31M in Series A funding.
The round was co-led by The round was co-led by Charles River Laboratories (NYSE: CRL) and Echo with participation from ATUM, Floating Point Advisors, Pine Ridge Ventures, Plains Venture Partners (a subsidiary of i2E), Seagull Capital, and Alloy Therapeutics.
The company intends to use the funds to complete its CGMP cell banking and drug substance manufacturing facility (500 L scale) in The Ziggurat, a downtown Oklahoma City office tower.
Led by CEO Dr. Jesse McCool, Chief Development Officer Dr. Brian Berquist, and Christian Kanady, Wheeler Bio is building a CDMO model that is focused on the paradigm for the gene-to-IND supply chain. Their primary service offering, Portable CMC, is an open source “CMC middleware” that operates by integrating discovery CROs and CDMOs. The Portable CMC includes a complement of integrated development services, including manufacturability assessments, stable pool and clone development, process and analytical method development, process demonstration, and technology transfer into CGMP production. In addition, the platform enhances key business integrations that speed up the translational steps for their clients while lowering technical, regulatory, and business risks.
FinSMEs
13/04/2023